Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial / Gahan PANDINA in Journal of Autism and Developmental Disorders, 37-2 (February 2007)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 37-2 (February 2007) . - p.367-373 Titre : Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial Type de document : Texte imprimé et/ou numérique Auteurs : Gahan PANDINA, Auteur ; Cynthia A. BOSSIE, Auteur ; Eriene YOUSSEF, Auteur ; Young ZHU, Auteur ; Fiona DUNBAR, Auteur Année de publication : 2007 Article en page(s) : p.367-373 Langues : Anglais (eng) Mots-clés : Autism Risperidone Behavioral-symptoms Hyperactivity Irritability Safety Index. décimale : PER Périodiques Résumé : Subgroup analysis of children (5–12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (n = 27) or placebo (n = 28); mean baseline ABC-I ( ± SD) was 20.6 (8.1) and 21.6 (10.2). Risperidone [mean dose ( ± SD): 1.37 mg/day (0.7)] resulted in significantly greater reduction from baseline to endpoint in ABC-I versus placebo [mean change ( ± SD): −13.4 (1.5) vs. −7.2 (1.4), P < 0.05; ES = −0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism. En ligne : http://dx.doi.org/10.1007/s10803-006-0234-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=641 [article] Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial [Texte imprimé et/ou numérique] / Gahan PANDINA, Auteur ; Cynthia A. BOSSIE, Auteur ; Eriene YOUSSEF, Auteur ; Young ZHU, Auteur ; Fiona DUNBAR, Auteur . - 2007 . - p.367-373. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 37-2 (February 2007) . - p.367-373 Mots-clés : Autism Risperidone Behavioral-symptoms Hyperactivity Irritability Safety Index. décimale : PER Périodiques Résumé : Subgroup analysis of children (5–12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (n = 27) or placebo (n = 28); mean baseline ABC-I ( ± SD) was 20.6 (8.1) and 21.6 (10.2). Risperidone [mean dose ( ± SD): 1.37 mg/day (0.7)] resulted in significantly greater reduction from baseline to endpoint in ABC-I versus placebo [mean change ( ± SD): −13.4 (1.5) vs. −7.2 (1.4), P < 0.05; ES = −0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism. En ligne : http://dx.doi.org/10.1007/s10803-006-0234-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=641

---

1 (1 - 1 / 1)